The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Octreotide 200 micrograms/ml solution for injection



Pfizer Healthcare IrelandPA0822/218/003

Main Information

Trade NameOctreotide 200 micrograms/ml solution for injection
Active SubstancesOCTREOTIDE ACETATE
Dosage FormSolution for injection
Licence HolderPfizer Healthcare Ireland
Licence NumberPA0822/218/003

Group Information

ATC CodeH01CB Somatostatin and analogues
H01CB02 octreotide

Status

License statusWithdrawn
Withdrawn Date19/05/2023
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back